Latest News on Rosuvastatin Research: Nov – 2019
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia
Background Despite the incontestable advantages of lipoprotein steroid alcohol (LDL-C) reduction in reducing the danger of coronary cardiovascular disease, several patients receiving lipid-lowering medical aid fail to attain LDL-C goals. we tend to compared the results of rosuvastatin and statin drug in reducing LDL-C and achieving LDL-C goals in patients with primary hypercholesteremia. strategies and ends up in this 52-week, randomized, double-blind, multicenter trial (4522IL/0026), 412 patients with LDL-C a hundred and sixty to. 
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
Large empirical studies, little prospective studies and post-hoc analyses of irregular clinical trials have instructed that statins may be helpful in patients with chronic cardiopathy. However, previous studies are methodologically weak. we tend to investigated the efficaciousness and safety of the statin drug rosuvastatin in patients with cardiopathy.We undertook a irregular, double-blind, placebo-controlled trial in 326 medical specialty and thirty one medical specialty centres in Italian Republic. we tend to registered patients aged eighteen years or older with chronic cardiopathy of recent royal line Heart Association category II-IV, regardless of cause and left bodily cavity ejection fraction, and haphazardly assigned them to rosuvastatin ten mg daily (n=2285) or placebo (n=2289) by a hid, processed phonephone randomization system. Patients were followed up for a median of three.9 years (IQR three.0-4.4). Primary endpoints were time to death, and time to death or admission to hospital for vas reasons. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, range NCT00336336.We analysed all irregular patients. 
Safety of rosuvastatin
The safety and tolerability of rosuvastatin were assessed (as of August 2003) mistreatment information from twelve,400 patients United Nations agency received five to forty mg of rosuvastatin during a international part II/III program, that delineated twelve,212 patient-years of continuous exposure to rosuvastatin. associate integrated info was wont to examine adverse events and laboratory information. In placebo-controlled trials, adverse events, regardless of relation assessment, occurred in fifty seven.4% of patients United Nations agency received five to forty mg of rosuvastatin (n = 744) and fifty six.8% of patients United Nations agency received placebo (n = 382). In fixed-dose trials with comparator statins, five to forty mg of rosuvastatin showed associate adverse event profile almost like those for ten to eighty mg of lipid-lowering medication, ten to eighty mg of statin drug, and ten to forty mg of lipid-lowering medicine. Clinically important elevations in aminoalkanoic acid transferase (>3 times the higher limit of normal) and amino acid enzyme (>10 times the upper limit of normal) were uncommon (≤0.2%) within the teams that received rosuvastatin and comparator statins. 
Potentiating NK cell activity by combination of Rosuvastatin and Difluoromethylornithine for effective chemopreventive efficacy against Colon Cancer
Colorectal cancer (CRC) is that the second highest reason behind cancer-related deaths. A eminent strategy to enhance chemopreventive efficacies is by down-regulating tumour polyamines and enhancing NK cell activities. Colonic carcinogenesis was iatrogenic by azoxymethane (AOM) in male F344 rats. Eight weeks once AOM treatment, animals were fed diets containing Rosuvastatin and difluromethylornithine (DFMO) singly and together for forty weeks. each agents showed vital suppression of glandular carcinoma multiplicity and incidence with no toxicity compared to untreated rats. Low-dose Rosuvastatin and DFMO suppressed colon glandular carcinoma multiplicity by seventy six compared to low-dose Rosuvastatin (29%) and DFMO (46%), suggesting additive effectualness. 
The Effect of Two Types of Statins (Rosuvastatin and Atorvastatin) on the Fertility of Male and Female Mice
Background: Studies showed contentious results relating to the result of statins on fertility parameters. many studies gift proof that statins have hurtful effects, others didn’t prove these effects.
Aim: to analyze the results of rosuvastatin and lipid-lowering medicine on elite fertility parameters in male and feminine mice, and to search out out their effects on initial and second generations of offspring.
Methods: For the primary generation studies, mice [30 males and sixty females] were allotted into four teams (6-8 females and 3-4 males, matched for age, in every of the four groups). Rosuvastatin (3.5 mg/kg) or lipid-lowering medicine (10.6 mg/kg) was administered once daily for twenty one days during a volume of zero.1 mil for every twenty g weight. range of live and dead pups, gestation success, pups weight, length of gestation, male to feminine magnitude relation, noninheritable anomalies, male bodily fluid androgen levels, testes weight and dimensions, and testes histopathology were followed. For the second generation studies, male and feminine offspring mice were mated and followed for fertility, gestation success, and sexual maturity. 
 Olsson, A.G., Istad, H., Luurila, O., Ose, L., Stender, S., Tuomilehto, J., Wiklund, O., Southworth, H., Pears, J., Wilpshaar, J.W. and Group, R.I., 2002. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. American Heart Journal, 144(6), (Web Link)
 Tavazzi, L., Maggioni, A.P., Marchioli, R., Barlera, S., Franzosi, M.G., Latini, R., Lucci, D., Nicolosi, G.L., Porcu, M. and Tognoni, G., 2008. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (London, England), 372(9645), (Web Link)
 Shepherd, J., Hunninghake, D.B., Stein, E.A., Kastelein, J.J., Harris, S., Pears, J. and Hutchinson, H.G., 2004. Safety of rosuvastatin. The American journal of cardiology, 94(7), (Web Link)
 Potentiating NK cell activity by combination of Rosuvastatin and Difluoromethylornithine for effective chemopreventive efficacy against Colon Cancer
Naveena B. Janakiram, Altaf Mohammed, Taylor Bryant, Yuting Zhang, Misty Brewer, Ashley Duff, Laura Biddick, Anil Singh, Stan Lightfoot, Vernon E Steele & Chinthalapally V. Rao
Scientific Reports volume 6, Article number: 37046 (2016) (Web Link)
 A. Bustan, A. and M. Jawad, A. (2017) “The Effect of Two Types of Statins (Rosuvastatin and Atorvastatin) on the Fertility of Male and Female Mice”, Journal of Advances in Medicine and Medical Research, 19(12), (Web Link)